Skip to main content

Breadcrumb

  1. Home

A Feasibility Study of the Millipede Transcatheter Annuloplasty Ring System in Patients With Functional Mitral Regurgitation

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about A Feasibility Study of the Millipede Transcatheter Annuloplasty Ring System in Patients With Functional Mitral Regurgitation

Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant

COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 210
  • Page 211
  • Page 212
  • Page 213
  • Page 214
  • Page 215
  • Page 216
  • Page 217
  • Page 218
  • …
  • Next page Next
  • Last page Last
Subscribe to